1.1 Meaning of immunology

Immunology is the study of biological mechanisms that recognise and respond to foreign, altered or potentially harmful material while maintaining tolerance to appropriate self components.

1.2 Early observations

Long before immune mechanisms were understood, observers recognised that survivors of some infections were less likely to develop the same disease again. Such observations established the practical idea of acquired protection.

1.3 Vaccination concept

The development of vaccination demonstrated that protective immunity could be induced deliberately without requiring the full natural disease. Later experimental work linked protection to cells and soluble factors.

1.4 Humoral and cellular ideas

Discovery of antibodies established a soluble arm of adaptive immunity, while studies of phagocytes and lymphocytes demonstrated that cells are equally central to defence.

1.5 Modern immunology

Contemporary immunology integrates molecular recognition, genetics, cell biology, microbiology and clinical laboratory science.

2.1 Definition

Innate immunity consists of rapidly available defence mechanisms encoded in the germ line. It recognises broad molecular patterns rather than generating a unique receptor through somatic rearrangement for every antigen.

2.2 Barriers

Skin, mucosal epithelium, mucus, ciliary movement, acidic environments and antimicrobial molecules reduce microbial entry.

2.3 Pattern recognition

Innate receptors detect conserved microbial structures and signals of tissue damage, triggering inflammation and antimicrobial responses.

2.4 Phagocytes

Neutrophils and macrophages ingest and destroy many microorganisms while releasing mediators that recruit or activate other cells.

2.5 Natural killer cells

Natural killer cells can recognise stressed or altered host cells and kill them without the antigen-specific priming required by conventional adaptive lymphocytes.

3.1 Inflammation

Inflammation is a coordinated vascular and cellular response to infection or tissue injury. Its purpose is to contain the cause, recruit defence and initiate repair.

3.2 Chemotaxis

Chemical gradients guide leukocytes toward sites where microbes or damaged tissues generate inflammatory signals.

3.3 Phagocytosis

Phagocytosis involves recognition and attachment, engulfment into a phagosome, fusion with destructive compartments and killing or digestion.

3.4 Opsonisation

Opsonins coat targets and increase efficient recognition by phagocyte receptors. Antibody and complement fragments can act as opsonins.

3.5 Resolution

Inflammation must eventually be limited; persistent or excessive inflammation can itself damage tissue.

4.1 Definition

Adaptive immunity develops highly specific responses through lymphocytes whose antigen receptors are generated by somatic gene rearrangement.

4.2 Specificity

Individual lymphocyte clones recognise particular molecular structures or epitopes.

4.3 Memory

After primary exposure, long-lived memory cells can produce faster and stronger responses on re-exposure.

4.4 Humoral immunity

B cells differentiate into antibody-secreting plasma cells, providing particularly important defence against extracellular targets and toxins.

4.5 Cell-mediated immunity

T lymphocytes coordinate immune responses or directly kill infected and altered cells.

5.1 Antigen

An antigen is a substance that can be specifically recognised by an antibody or antigen receptor. An immunogen is capable of inducing an immune response.

5.2 Epitopes

An epitope is the particular molecular region recognised by an antibody or lymphocyte receptor.

5.3 Determinants of immunogenicity

Foreignness, molecular size, chemical complexity, physical form, dose, route and host genetics influence immunogenicity.

5.4 Haptens

A hapten can bind specifically to antibody but may require attachment to a larger carrier to induce a strong immune response.

5.5 Cross-reactivity

Structurally related epitopes can allow an antibody or receptor generated against one antigen to react with another.

6.1 Basic structure

An antibody molecule contains two identical heavy chains and two identical light chains linked by covalent and non-covalent interactions.

6.2 Variable regions

Variable domains form antigen-binding sites whose sequence diversity determines specificity.

6.3 Constant regions

Constant heavy-chain regions determine immunoglobulin class and many effector functions.

6.4 Fab and Fc

Fab portions contain antigen-binding sites, while the Fc region interacts with receptors and complement according to antibody class.

6.5 Classes

The major human immunoglobulin classes are IgM, IgG, IgA, IgE and IgD, each adapted to particular anatomical and functional roles.

7.1 Origin

B-cell precursors arise from haematopoietic stem cells and undergo development primarily in bone marrow in mammals.

7.2 Receptor formation

Immunoglobulin gene rearrangement generates diverse B-cell receptors before antigen exposure.

7.3 Selection

Developing cells that strongly recognise self components can be deleted, edited or functionally silenced, contributing to tolerance.

7.4 Activation

Antigen binding plus appropriate signals stimulates selected B cells to proliferate and differentiate.

7.5 Plasma and memory cells

Activated B cells can become antibody-secreting plasma cells or long-lived memory cells.

8.1 Origin and thymus

T-cell precursors originate from haematopoietic tissues and mature in the thymus.

8.2 T-cell receptor

T cells express clonally distributed antigen receptors generated by gene rearrangement.

8.3 MHC restriction

Conventional T cells recognise peptide antigen presented by major histocompatibility complex molecules rather than free native antigen.

8.4 CD4 T cells

CD4 helper T cells coordinate immune responses through cytokines and interactions with other cells.

8.5 CD8 T cells

CD8 cytotoxic T cells can recognise and kill infected or altered host cells displaying appropriate antigen.

9.1 MHC function

MHC molecules display peptide fragments for recognition by T cells.

9.2 MHC class I

Class I molecules are expressed on most nucleated cells and present mainly intracellularly derived peptides to CD8 T cells.

9.3 MHC class II

Class II molecules are expressed mainly by professional antigen-presenting cells and present peptides derived largely from internalised material to CD4 T cells.

9.4 Antigen-presenting cells

Dendritic cells are especially effective at initiating naïve T-cell responses; macrophages and B cells also present antigen.

9.5 Significance

MHC diversity influences transplantation, disease associations and population-level immune recognition.

10.1 Cytokines

Cytokines are small signalling proteins that regulate activation, differentiation, migration and survival of immune cells.

10.2 Local action

Many cytokines act over short distances and can have overlapping or context-dependent effects.

10.3 Chemokines

Chemokines are specialised cytokines that direct cell migration.

10.4 Networks

Immune responses depend on cytokine networks rather than isolated molecules; one cytokine can induce others or change receptor expression.

10.5 Clinical importance

Excess cytokine activity can contribute to inflammatory disease, while therapeutic blockade or supplementation can modify immune responses.

11.1 Definition

Complement is a network of plasma and membrane-associated proteins activated through regulated proteolytic cascades.

11.2 Pathways

Classical, lectin and alternative pathways use different initiating mechanisms but converge on central complement activation.

11.3 Opsonisation

C3-derived fragments coat microbial surfaces and promote phagocytosis.

11.4 Inflammation

Small complement fragments recruit and activate inflammatory cells.

11.5 Membrane attack complex

Terminal complement components can form pores in susceptible membranes, while host regulatory proteins protect self cells.

12.1 Helper responses

Activated CD4 T cells differentiate into functional subsets that support macrophages, B cells and other immune effectors.

12.2 Cytotoxicity

Cytotoxic T cells kill target cells through regulated release of cytotoxic molecules or death-receptor pathways.

12.3 Macrophage activation

T-cell-derived signals can enhance macrophage killing of intracellular microorganisms.

12.4 NK-cell cytotoxicity

Natural killer cells provide rapid cytotoxic defence and can participate in antibody-dependent cellular cytotoxicity.

12.5 Coordination

Effective immunity often combines antibodies, complement, phagocytes and T cells rather than relying on one arm.

13.1 Primary response

Initial antigen exposure activates rare naïve lymphocytes and requires time for clonal expansion and differentiation.

13.2 Secondary response

Memory lymphocytes respond more rapidly and often more strongly upon subsequent exposure.

13.3 Affinity maturation

Activated B-cell populations can undergo selection that increases average antibody affinity.

13.4 Class switching

B cells can change antibody heavy-chain constant regions while retaining antigen specificity, altering effector function.

13.5 Vaccination relevance

Vaccines exploit memory so protective responses are available before natural exposure to the pathogen.

14.1 Tolerance

Immunological tolerance is specific non-responsiveness to an antigen, especially important for preventing damaging responses to self.

14.2 Central tolerance

Developing lymphocytes encountering self antigens in primary lymphoid organs can be deleted or altered.

14.3 Peripheral tolerance

Mature self-reactive cells can be controlled through anergy, deletion, inhibitory receptors and regulatory cells.

14.4 Regulatory T cells

Regulatory T cells suppress inappropriate activation and help maintain immune homeostasis.

14.5 Immunosuppression

Immune responses can be reduced by physiological regulation, disease or therapeutic drugs; suppression can protect against harmful immunity but increase infection risk.

15.1 Graft types

Autografts come from the same individual, isografts from genetically identical individuals, allografts from genetically different members of the same species, and xenografts across species.

15.2 Allorecognition

Recipient T cells can recognise donor MHC molecules or donor-derived peptides as foreign.

15.3 Rejection

Hyperacute, acute and chronic rejection involve different mechanisms and time courses.

15.4 Graft-versus-host disease

Immunocompetent donor cells can attack recipient tissues, particularly after haematopoietic cell transplantation.

15.5 Control

Compatibility testing and immunosuppression reduce rejection but must be balanced against infection and malignancy risk.

16.1 Meaning

Hypersensitivity refers to immune responses that cause tissue injury rather than useful protection.

16.2 Type I

Immediate hypersensitivity is mediated by IgE, mast cells and rapidly released mediators after allergen exposure.

16.3 Type II

Antibody-mediated reactions target cell-surface or matrix antigens and can recruit complement or effector cells.

16.4 Type III

Immune-complex disease results when antigen-antibody complexes deposit or form in tissues and trigger inflammation.

16.5 Type IV

Delayed-type hypersensitivity is primarily T-cell mediated and develops more slowly than immediate antibody-mediated reactions.

17.1 Autoimmunity

Autoimmune disease occurs when immune responses against self antigens cause pathological injury.

17.2 Breakdown of tolerance

Genetic susceptibility, infection, tissue damage and environmental factors can contribute to loss of tolerance.

17.3 Immunodeficiency

Defects in immune components can be inherited or acquired and increase susceptibility to characteristic infections.

17.4 Lymphoproliferative disorders

Uncontrolled expansion of immune cells can disrupt normal immunity and tissue function.

17.5 Principle

Immune disease can result from too little immunity, misdirected immunity or excessive immunity.

18.1 Purpose

Diagnostic immunology uses antigen-antibody reactions, cellular measurements and molecular immune markers to detect disease, exposure or immune status.

18.2 Sensitivity and specificity

Sensitivity measures detection among truly positive cases, while specificity measures correct exclusion among truly negative cases.

18.3 Predictive value

Positive and negative predictive values depend on test performance and disease prevalence in the tested population.

18.4 Controls

Positive, negative and procedural controls are essential for distinguishing true reaction from assay failure.

18.5 Interpretation

No immunological test should be interpreted without specimen quality, timing, clinical context and limitations.

19.1 Precipitation

Soluble antigen and antibody can form visible lattices when present in suitable proportions.

19.2 Agglutination

Particulate antigens such as cells or coated particles can be cross-linked by antibodies to produce visible clumping.

19.3 Prozone and postzone

Excess antibody or excess antigen can prevent optimal lattice formation and yield unexpectedly weak reactions.

19.4 Titration

Serial dilution can estimate the highest dilution showing a defined positive reaction.

19.5 Applications

Agglutination principles are used in blood grouping, serology and particle-based assays.

20.1 ELISA principle

Enzyme-linked immunosorbent assays convert specific antigen-antibody binding into a measurable enzyme-generated signal.

20.2 Direct and indirect formats

Assay architecture determines whether antigen or antibody is being measured and how signal amplification occurs.

20.3 Sandwich assays

Capture and detection antibodies bind different epitopes on an antigen, increasing specificity.

20.4 Competitive assays

Sample analyte competes with a labelled or immobilised component, often producing an inverse relation between analyte and signal.

20.5 Quality

Standards, blanks and controls are required to interpret optical measurements correctly.

21.1 Immunofluorescence

Fluorophore-labelled antibodies permit visualisation of antigen distribution or antibody binding under fluorescence microscopy.

21.2 Direct method

A labelled primary antibody binds the target directly.

21.3 Indirect method

An unlabelled primary antibody is detected by a labelled secondary antibody, allowing signal amplification.

21.4 Immunoblotting

Proteins separated by electrophoresis can be transferred to a membrane and probed with specific antibodies.

21.5 Interpretation

Band position, controls and assay validation matter; a visible band alone is not automatically diagnostic.

22.1 Principle

Flow cytometry analyses individual cells as they pass through a focused detection region.

22.2 Scatter

Forward and side scatter provide information related to cell size and internal complexity.

22.3 Fluorescent markers

Antibodies labelled with different fluorophores identify cell-surface or intracellular molecules.

22.4 Gating

Gating defines cell populations for analysis and must be based on appropriate controls.

22.5 Applications

Flow cytometry can enumerate lymphocyte subsets, characterise immune phenotypes and assess cell function.

23.1 Extracellular bacteria

Antibodies, complement and phagocytes are important against many extracellular bacteria.

23.2 Intracellular bacteria

Cell-mediated responses and activated macrophages are particularly important when bacteria survive within host cells.

23.3 Viruses

Neutralising antibodies can prevent viral entry, while cytotoxic T cells remove infected cells.

23.4 Interferons

Innate antiviral interferons induce cellular states that restrict viral replication and coordinate defence.

23.5 Evasion

Pathogens can vary antigens, block immune signalling or hide within cells, shaping the type of protective response required.

24.1 Large parasites

Helminths are too large for ordinary phagocytosis, so immunity uses antibody, eosinophils, mast cells and tissue responses.

24.2 Protozoa

Protozoan parasites occupy extracellular or intracellular niches and require different combinations of antibodies, phagocytes and T cells.

24.3 Antibody-dependent killing

Antibodies can coat parasite surfaces and recruit effector cells bearing Fc receptors.

24.4 Evasion

Parasites can vary antigens, occupy protected sites or modulate host immunity.

24.5 Pathology

Strong anti-parasite responses can also contribute to tissue injury, fibrosis or allergy-like reactions.

25.1 Plant immunity

Plants lack circulating antibodies and mobile lymphocytes but possess sophisticated innate immune systems in individual cells and tissues.

25.2 Pattern recognition

Plant surface receptors detect conserved microbial patterns and activate defence.

25.3 Effector recognition

Intracellular resistance proteins can recognise pathogen effectors directly or indirectly and trigger stronger responses.

25.4 Local defence

Cell-wall reinforcement, antimicrobial compounds and programmed cell death can restrict pathogens.

25.5 Systemic responses

Signals from infected tissue can prime distant parts of the plant for enhanced resistance.

26.1 Vaccination

Vaccination exposes the immune system to antigen in a form designed to induce protective memory with lower risk than natural disease.

26.2 Live attenuated vaccines

These contain weakened organisms capable of limited replication and often generate broad durable responses.

26.3 Inactivated vaccines

Killed organisms cannot replicate but may require repeated doses or adjuvants.

26.4 Subunit and conjugate vaccines

Purified components focus immunity on selected antigens; conjugation can improve responses to poorly immunogenic polysaccharides.

26.5 Genetic platforms

Viral-vector and nucleic-acid vaccines deliver genetic instructions for host cells to produce antigen.

27.1 Adjuvant

An adjuvant enhances or shapes immune responses to a vaccine antigen.

27.2 Prime and boost

Initial priming activates naïve lymphocytes, while booster doses expand and mature memory responses.

27.3 Route

Intramuscular, subcutaneous, oral, intradermal or mucosal routes create different practical and immunological conditions.

27.4 Age and host factors

Immune maturity, previous exposure and immunosuppression influence vaccine responses.

27.5 Schedule

Schedules are designed from evidence about safety, immune kinetics and disease risk rather than arbitrary intervals.

28.1 Antigen source

Production begins with a defined antigen platform such as attenuated organism, inactivated organism, purified protein, vector or nucleic acid.

28.2 Seed and cell banks

Controlled master and working banks maintain identity and consistency of biological starting materials.

28.3 Upstream production

Organisms, cells or recombinant systems are cultivated under controlled conditions to generate antigen.

28.4 Purification and formulation

Product is purified as required, formulated with stabilisers or adjuvants and filled under controlled conditions.

28.5 Quality control

Identity, potency, purity, sterility or microbial quality, safety and consistency are assessed according to the product and applicable requirements.

29.1 Veterinary purpose

Animal vaccines protect livestock, poultry, companion animals or other species and can support food security and zoonotic disease control.

29.2 Species specificity

Immune responses, disease ecology, dose and route vary among animal species.

29.3 Production

The same broad principles of defined seed, controlled propagation, inactivation or attenuation where applicable, formulation and quality control apply.

29.4 Field effectiveness

Cold chain, maternal antibodies, vaccination technique and pathogen variation can affect real-world protection.

29.5 One Health

Veterinary vaccination can reduce animal suffering, economic loss and transmission of selected pathogens at the human-animal interface.

Concept

Each naïve B or T lymphocyte expresses receptors of one principal specificity. Antigen does not instruct a cell to manufacture an entirely new receptor; instead it selects rare pre-existing clones whose receptors recognise it.

Mechanism

Selected clones proliferate and differentiate into effector and memory populations. This converts a rare recognition event into a response containing many cells of useful specificity.

Significance

Clonal selection explains specificity, memory and why adaptive responses require time after first exposure.

Concept

B- and T-cell receptor genes are assembled from multiple gene segments during lymphocyte development. Random combinations create enormous diversity before antigen exposure.

Mechanism

Additional diversity arises at the junctions where gene segments are joined. B cells can later diversify antibody genes further during activated responses.

Significance

The benefit is broad recognition capacity; the accompanying risk of self-reactivity makes tolerance mechanisms essential.

Concept

Activated B cells in germinal centres can acquire mutations in immunoglobulin variable-region genes. Cells whose receptors bind antigen more effectively receive stronger survival and proliferation signals.

Mechanism

Repeated cycles of mutation and selection increase the average affinity of antibodies produced during a response.

Significance

This is one reason booster immunisation can improve antibody quality as well as quantity.

Concept

An activated B cell can replace the heavy-chain constant region used by its antibody while preserving the rearranged variable region that determines antigen specificity.

Mechanism

Cytokines and cell interactions influence whether IgG, IgA, IgE or another class is produced.

Significance

Class switching allows one antigen specificity to recruit different effector mechanisms at blood, mucosal or tissue sites.

Concept

IgM is the first major antibody class produced in many primary responses. Secreted IgM commonly forms a pentamer with high overall avidity for multivalent antigens.

Mechanism

Its multiple binding sites make it efficient at agglutination and classical complement activation.

Significance

Membrane IgM also serves as part of the antigen receptor on naïve B cells.

Concept

IgG is abundant in blood and extracellular fluid and dominates many secondary responses. Different IgG subclasses have distinct functional properties.

Mechanism

IgG can neutralise toxins or viruses, opsonise targets and activate complement depending on subclass.

Significance

Maternal IgG can cross the human placenta, providing temporary passive protection to the fetus and newborn.

Concept

IgA is prominent in mucosal secretions such as saliva, intestinal fluid and breast milk. Secretory IgA is commonly dimeric and associated with a secretory component.

Mechanism

It helps prevent microbial attachment and neutralises antigens at mucosal surfaces with relatively limited inflammation.

Significance

Its distribution makes it especially important where pathogens first contact epithelial barriers.

Concept

IgE binds high-affinity receptors on mast cells and basophils. Cross-linking by allergen can trigger rapid mediator release.

Mechanism

IgE also participates in defence against some helminths by helping recruit and activate effector mechanisms.

Significance

The same pathway that contributes to parasite defence can generate allergic disease when directed against harmless environmental antigens.

Concept

IgD is expressed mainly on naïve mature B cells together with IgM and functions as part of the B-cell receptor complex.

Mechanism

Its serum concentration is low compared with major secreted immunoglobulin classes.

Significance

Its presence illustrates that antibody molecules function not only as soluble effectors but also as cell-surface antigen receptors.

Concept

Affinity describes strength of one antigen-binding site interacting with one epitope, whereas avidity describes the combined strength of multiple interactions.

Mechanism

A multivalent IgM molecule can show high avidity even when individual binding sites have modest affinity.

Significance

The distinction matters when interpreting serological maturation and the stability of immune complexes.

Concept

Neutralising antibodies bind microbial surface molecules or toxins in ways that prevent attachment, entry or biological activity.

Mechanism

Neutralisation does not necessarily kill the pathogen directly; it blocks a critical functional step and allows clearance by other mechanisms.

Significance

Vaccine development often seeks antibodies directed at accessible neutralising epitopes.

Concept

Opsonisation coats a particle with molecules recognised efficiently by phagocyte receptors. IgG Fc regions and complement fragments are major examples.

Mechanism

The phagocyte binds the opsonised surface more strongly and internalises it more efficiently.

Significance

This mechanism connects adaptive antibody specificity with innate phagocytic killing.

Concept

The classical pathway is initiated when C1 interacts appropriately with antibodies bound to antigen or with selected other activators.

Mechanism

Sequential proteolysis generates a C3 convertase, leading to extensive C3 activation.

Significance

Because free antibody is a poor trigger compared with antigen-bound antibody, complement activation is concentrated at immune complexes or target surfaces.

Concept

The alternative pathway can amplify complement activation on surfaces that lack adequate host regulatory protection.

Mechanism

It does not require antigen-specific antibody for initiation and therefore contributes to innate defence.

Significance

Host cells express regulators that restrict amplification, illustrating the need to distinguish microbial from self surfaces.

Concept

The lectin pathway begins when pattern-recognition molecules bind particular microbial carbohydrates and activate associated proteases.

Mechanism

Downstream reactions converge with the classical pathway at formation of a C3 convertase.

Significance

This provides antibody-independent recognition while using a shared complement effector system.

Concept

Complement is potentially damaging because activated components can attack nearby membranes and amplify inflammation.

Mechanism

Soluble and membrane-bound regulators accelerate convertase decay, inactivate components or block terminal pore formation.

Significance

Defects in regulation can produce host tissue injury, demonstrating that immune protection requires restraint as well as activation.

Concept

Dendritic cells capture antigen in peripheral tissues and, after activation, migrate to lymphoid organs where they present peptides and provide co-stimulatory signals to naïve T cells.

Mechanism

Their maturation changes antigen uptake, MHC expression and cytokine production.

Significance

They therefore form a bridge between innate sensing of infection and initiation of adaptive immunity.

Concept

Recognition of peptide-MHC by a T-cell receptor is necessary but usually insufficient for full activation of a naïve T cell.

Mechanism

Co-stimulatory receptor-ligand interactions and cytokines provide information about danger and the nature of the infection.

Significance

Antigen recognition without appropriate co-stimulation can promote non-responsiveness, helping prevent accidental activation against harmless or self antigens.

Concept

Th1-type responses support macrophage activation and cell-mediated defence against many intracellular microorganisms.

Mechanism

Their cytokines enhance microbicidal functions and influence antibody class selection.

Significance

Excessive Th1-associated inflammation can also contribute to tissue damage, illustrating the balance between defence and pathology.

Concept

Th2-type responses promote IgE production, eosinophil activity and defence against helminths.

Mechanism

They are also central to many allergic disorders when activated against otherwise harmless antigens.

Significance

The same effector programme can therefore be protective or pathological depending on its target and magnitude.

Concept

Th17-type cells produce cytokines that recruit neutrophils and strengthen barrier defence, particularly against selected extracellular bacteria and fungi.

Mechanism

They are important at mucosal surfaces where rapid neutrophil mobilisation can restrict invasion.

Significance

Dysregulated Th17 responses can contribute to chronic inflammatory and autoimmune disease.

Concept

Regulatory T cells suppress excessive or self-reactive immune responses through inhibitory cytokines, receptor-mediated effects and competition for growth signals.

Mechanism

They support peripheral tolerance and limit collateral tissue damage after infection.

Significance

Too little regulation can promote autoimmunity, whereas excessive suppression can weaken useful anti-pathogen or anti-tumour responses.

Concept

CD8 T cells inspect peptide-MHC I complexes and can kill cells displaying foreign or abnormal intracellular antigens.

Mechanism

Cytotoxic granules containing perforin and granzymes trigger controlled target-cell death, while death-receptor pathways provide another mechanism.

Significance

Targeted killing removes cellular factories used by viruses or some intracellular pathogens while limiting indiscriminate tissue destruction.

Concept

NK cells integrate activating and inhibitory receptor signals. Healthy cells expressing appropriate MHC I generate inhibitory signals, whereas stressed or altered cells can shift the balance toward activation.

Mechanism

This allows rapid killing of some infected or transformed cells before antigen-specific T-cell responses expand.

Significance

Antibody-coated targets can also be recognised through Fc receptors, linking NK cells to adaptive immunity.

Concept

Mucosal surfaces are major entry points for microorganisms but must also tolerate food and commensal organisms.

Mechanism

Secretory IgA, epithelial barriers, antimicrobial molecules and specialised lymphoid tissues provide defence with controlled inflammation.

Significance

Excessive mucosal inflammation would damage absorption and gas-exchange surfaces, so regulation is especially important.

Concept

Passive immunity results from transfer of preformed antibodies rather than activation of the recipient's own adaptive response.

Mechanism

Maternal antibodies and administered immunoglobulin can provide immediate protection, but protection wanes as transferred antibodies are degraded.

Significance

Because recipient memory is not generated, passive protection differs fundamentally from active vaccination.

Concept

Active immunity follows infection or vaccination when the individual's lymphocytes respond to antigen and form effector and memory populations.

Mechanism

Protection develops less immediately than passive antibody transfer but can persist much longer.

Significance

Vaccination aims to create active immunity without the disease burden associated with natural infection.

Concept

Primary immunodeficiencies arise from inherited defects affecting immune development or function. The pattern of infection reflects the component affected.

Mechanism

Antibody defects predispose particularly to certain extracellular infections, while severe T-cell defects impair multiple arms of adaptive immunity.

Significance

Studying these disorders has revealed normal functions of immune genes and pathways.

Concept

Acquired immunodeficiency develops after birth because of infection, malnutrition, malignancy, immunosuppressive treatment or other conditions.

Mechanism

The degree and type of immune defect determine which opportunistic infections become likely.

Significance

Laboratory assessment should therefore target the suspected immune component rather than ordering unrelated tests.

Concept

Autoantibodies recognise self antigens. Their presence can contribute directly to disease, serve as markers of immune dysregulation or occasionally occur without overt illness.

Mechanism

Diagnostic value depends on specificity, titre, disease prevalence and clinical context.

Significance

A positive autoantibody result is therefore evidence to interpret, not a diagnosis by itself.

Concept

Microbial antigens can sometimes resemble host structures sufficiently that immune responses cross-react with self tissues.

Mechanism

This is one proposed route by which infection can contribute to autoimmunity in susceptible individuals.

Significance

Similarity alone does not prove causation; genetic and regulatory factors determine whether cross-reactivity becomes disease.

Concept

Initial allergen exposure can stimulate Th2 responses and IgE class switching. IgE binds mast-cell Fc receptors and sensitises the cell.

Mechanism

On later exposure, allergen cross-links cell-bound IgE and triggers rapid release of histamine and other mediators.

Significance

The resulting vascular, smooth-muscle and inflammatory effects range from local allergy to systemic anaphylaxis.

Concept

IgG or IgM can bind antigens on cell surfaces or extracellular structures and recruit complement, phagocytes or receptor-altering effects.

Mechanism

Damage is directed toward the location of the target antigen rather than deposition of circulating immune complexes.

Significance

Examples differ mechanistically: antibodies can destroy cells, inflame tissues or stimulate/block receptors.

Concept

When soluble antigen and antibody form complexes that are not cleared efficiently, complexes can deposit in vessels or tissues.

Mechanism

Complement activation and recruited neutrophils then produce inflammation and tissue injury.

Significance

The amount, size and clearance of complexes influence where pathology develops.

Concept

Sensitised T cells recognise antigen and release cytokines or directly kill target cells. Because cellular recruitment and activation take time, reactions are delayed compared with IgE-mediated allergy.

Mechanism

Macrophage activation can produce persistent inflammation when antigen remains.

Significance

This mechanism underlies important contact reactions, diagnostic skin responses and some autoimmune tissue injury.

Concept

Pre-existing recipient antibodies against donor antigens can bind graft vessels almost immediately after transplantation.

Mechanism

Complement activation, endothelial injury and thrombosis rapidly compromise blood supply.

Significance

Compatibility testing before transplantation aims to prevent this catastrophic antibody-mediated reaction.

Concept

Recipient T cells and antibodies can attack donor tissue over days to months, although timing varies with treatment and prior sensitisation.

Mechanism

Cellular rejection involves lymphocyte recognition of donor antigens, while antibody-mediated forms injure graft vasculature.

Significance

Immunosuppressive therapy reduces risk but requires monitoring because excessive suppression increases infection.

Concept

Chronic rejection develops gradually through vascular narrowing, fibrosis and progressive loss of graft function.

Mechanism

Multiple immune and nonimmune injuries contribute, and established structural damage is difficult to reverse.

Significance

Long-term graft survival therefore depends on more than controlling early acute rejection.

Concept

Sensitivity is the proportion of people with the target condition who test positive. A highly sensitive test produces relatively few false negatives.

Mechanism

Sensitivity is an intrinsic performance characteristic measured against an appropriate reference standard, not simply the percentage of all tests that are positive.

Significance

Screening strategies often value high sensitivity when missing disease has serious consequences.

Concept

Specificity is the proportion of people without the target condition who test negative. High specificity produces relatively few false positives.

Mechanism

Cross-reactivity can reduce specificity when antibodies recognise related antigens.

Significance

Confirmatory tests may emphasise specificity when an incorrect positive diagnosis would cause harm.

Concept

Positive predictive value is the probability that a person with a positive result truly has the condition in the tested population.

Mechanism

Even an accurate test can have low positive predictive value when disease prevalence is very low because false positives can outnumber true positives.

Significance

Predictive value therefore changes with population and cannot be copied blindly from one setting to another.

Concept

Seroconversion describes the development of detectable specific antibody in blood after infection or immunisation.

Mechanism

Timing matters because a sample collected too early can be negative despite true infection.

Significance

Paired samples demonstrating a new response or significant change can sometimes provide stronger evidence than one isolated measurement.

Concept

A titre is commonly reported as the reciprocal of the highest sample dilution that still produces a defined positive reaction.

Mechanism

A titre of 1:320 is higher than 1:40 because antibody remains detectable after greater dilution.

Significance

Titre is method-dependent; comparisons require the same assay and interpretive rules.

Concept

Vaccine efficacy describes protection measured under controlled study conditions, while effectiveness describes performance in routine populations.

Mechanism

Effectiveness can be influenced by coverage, cold chain, host characteristics, pathogen circulation and programme delivery.

Significance

Neither value means every vaccinated individual is guaranteed protection.

Concept

When vaccination reduces infection or transmission, unvaccinated individuals can receive indirect protection because encounters with infectious persons become less frequent.

Mechanism

The magnitude depends on pathogen transmissibility, vaccine effect on transmission, coverage and population mixing.

Significance

Herd effects are population phenomena and do not eliminate the value of individual protection.

Concept

Clinical trials identify common reactions and many important safety outcomes before authorisation, but extremely rare events may become clearer only after millions of doses.

Mechanism

Post-marketing surveillance therefore complements pre-licensure evidence.

Significance

A reported event after vaccination is not automatically caused by the vaccine; observed rates must be compared with expected background events and investigated.

Concept

Many vaccines require defined temperature ranges during storage and transport because biological components can lose potency after inappropriate heat or freezing exposure.

Mechanism

Temperature monitoring and validated storage equipment protect product quality from manufacturer to administration site.

Significance

A vaccine that looks normal can have reduced potency after temperature damage, so appearance is not a sufficient quality check.

Concept

Adjuvants can retain antigen, activate innate sensing or shape antigen presentation, thereby improving adaptive responses.

Mechanism

They can reduce the amount of antigen or number of doses needed for some vaccines.

Significance

Adjuvant choice is formulation-specific; stronger inflammation is not automatically better immunity.

Concept

Biological manufacturing begins with characterised seed lots or cell banks to minimise uncontrolled variation between batches.

Mechanism

Critical process parameters are monitored, and each lot undergoes defined quality tests before release.

Significance

Consistency is essential because vaccine performance depends on reproducible identity, potency, purity and stability.

Concept

Parasites can change surface antigens, shed antibodies, occupy intracellular sites or manipulate host cytokines.

Mechanism

Long life cycles and multiple developmental stages expose different antigens at different times.

Significance

These strategies make sterilising immunity difficult and explain why natural infection does not always produce complete durable protection.

Concept

Plant pattern-recognition receptors at the cell surface detect conserved microbial molecules and activate signalling, reactive oxygen responses, cell-wall reinforcement and defence gene expression.

Mechanism

Pathogens can secrete effectors that suppress these responses.

Significance

Plant resistance therefore reflects an evolutionary contest between host detection and pathogen interference.

Concept

Intracellular plant resistance proteins can detect particular pathogen effectors or the changes they cause in host targets.

Mechanism

Recognition often triggers a strong local defence that can include programmed cell death around the infection site.

Significance

This limits biotrophic pathogens that require living host tissue and demonstrates immune recognition without antibodies or lymphocytes.

Use prepared blood-film images to distinguish major leukocyte classes. Relate neutrophils to rapid phagocytic defence, lymphocytes to adaptive and NK functions, monocytes to macrophage precursors, eosinophils to helminth/allergic responses and basophils to inflammatory mediator release.

A differential count is a distribution of cell types, not a diagnosis by itself.

Examine prepared sections or images of lymph node, spleen and thymus and identify their major regions.

Relate architecture to function: lymph nodes sample lymph, spleen monitors blood, and thymus supports T-cell maturation.

Observe a safe validated demonstration in which antibody bridges particulate antigens to produce visible clumping.

Include positive and negative controls; antigen or antibody excess can weaken lattice formation.

Interpret a two-fold dilution series and identify the last dilution meeting the positive criterion.

If 1:160 is the final positive dilution, the titre is reported as 160; the value is assay-specific.

Study a gel precipitation demonstration in which soluble antigen and antibody form visible precipitate at suitable proportions.

Interpret only with controlled reagents because concentration strongly affects the pattern.

Use supplied absorbance data containing blanks, controls and cut-off information. Verify controls before classifying unknowns.

Do not invent a universal optical-density cut-off; thresholds are assay-specific.

Trace capture antibody, antigen, detection antibody and labelled signal system.

Binding of two antibodies to distinct antigenic sites can increase analytical specificity.

Trace immobilised antigen, sample antibody and labelled anti-immunoglobulin.

Timing after exposure affects whether specific antibody is detectable.

Study a prepared blot with size markers, controls and sample lanes.

Band position, antigen specificity and control performance all matter.

Compare direct and indirect immunofluorescence and identify the labelled reagent in each.

Record staining distribution and pattern rather than fluorescence alone.

Use a provided dot plot to define a cell population and inspect labelled markers.

Gating and fluorescence controls affect calculated population percentages.

Interpret a conceptual assay in which antibody-coated targets are lysed when a complement pathway functions.

Reduced haemolysis can indicate pathway dysfunction but requires validated diagnostic interpretation.

Use authorised blood-grouping results to connect red-cell antigens with antibody-mediated agglutination.

Transfusion compatibility involves antigen-antibody principles beyond memorising ABO letters.

Compare one antibody's reactions with a target antigen and structurally related antigens.

Controls distinguish intended recognition from nonspecific binding.

From a 2×2 table calculate sensitivity = TP/(TP+FN) and specificity = TN/(TN+FP).

Always state the reference standard and tested population.

Calculate PPV = TP/(TP+FP) and NPV = TN/(TN+FN).

Explain why predictive values change with prevalence.

Plot antibody concentration after primary vaccination and booster exposure.

Identify lag, primary peak, memory response and decline.

Trace deposition of C3 fragments on a microbial surface and recognition by phagocyte complement receptors.

Explain why complement improves phagocytosis without directly lysing every target.

Classify supplied scenarios by immediate IgE, antibody, immune-complex or T-cell mechanisms.

Justify each answer using timing and effector mechanism.

Interpret a simplified donor-recipient compatibility dataset.

Explain conceptually the roles of ABO, HLA and crossmatching.

Compare infection patterns associated with antibody, T-cell, phagocyte and complement defects.

Use mechanistic reasoning rather than diagnosing from one symptom.

Trace Th2 cytokines, IgE, mast cells and eosinophils in a helminth response.

Explain why large parasites require extracellular killing mechanisms.

Analyse pattern recognition, pathogen effector interference and resistance-protein activation.

Contrast plant innate defence with vertebrate antibody-based adaptive immunity.

Arrange seed/cell bank, propagation, harvest, processing, formulation, filling, quality control and distribution.

Identify stages protecting identity, purity, potency and consistency.

Interpret a temperature logger showing an excursion outside the specified range.

Disposition requires product-specific stability evidence rather than visual inspection.

Memory B and T cells formed after priming are more numerous and activate faster than the original naïve clones.

Memory B cells can generate high-affinity class-switched antibodies and memory T cells accelerate cellular defence.

This explains the faster secondary response after booster vaccination.

A highly specific assay is used where disease is very rare.

A small false-positive fraction applied to a large negative population can produce appreciable positive results.

Confirmatory testing and population-specific predictive values are essential.

A sample collected immediately after infection is antibody-negative although infection is present.

Antibody production requires clonal activation and differentiation, creating a diagnostic window.

Timing must be considered before interpreting a negative result.

Allergen cross-links IgE already bound to mast cells in a sensitised person.

Rapid mediator release causes vascular and airway effects.

This systemic Type I reaction shows how protective machinery can become harmful.

Persistent soluble antigen forms complexes with antibody that deposit in tissues.

Complement and recruited neutrophils produce inflammation.

The target tissue need not originally contain the antigen.

A small chemical modifies skin proteins and sensitised T cells respond after re-exposure.

The reaction develops over many hours because cellular recruitment is required.

This distinguishes Type IV from immediate IgE hypersensitivity.

Recipient lymphocytes recognise donor HLA molecules or donor peptides.

Cellular and antibody responses can damage graft tissue.

Immunosuppression reduces rejection but increases infection risk.

Recurrent infections suggest failure of one complement function.

Different component defects affect opsonisation, inflammation or terminal lysis differently.

Functional pathway assays can help localise the defect.

A multicellular parasite is too large for ordinary phagocytosis.

Th2 responses, IgE, eosinophils and mast cells coordinate extracellular defence.

The same response can contribute to tissue pathology.

A virus replicates inside host cells where circulating antibody cannot reach most replication machinery.

Neutralising antibodies block new infection while cytotoxic T cells remove infected cells.

Antiviral defence therefore combines humoral and cellular immunity.

A capsule impairs direct phagocyte recognition.

Specific antibody and complement coat the bacterium for Fc- and complement-receptor binding.

This illustrates the protective value of opsonisation.

Maternal IgG reaches the fetus and secretory IgA is supplied in breast milk.

Protection is immediate but does not create infant antigen-specific memory.

Passive protection wanes when transferred antibody is no longer supplied or is degraded.

A live attenuated vaccine can replicate to a limited degree whereas an inactivated vaccine cannot.

Live platforms often stimulate broad responses; inactivated products may need adjuvant or repeated doses.

Platform choice balances immunogenicity, safety, target population and manufacturing.

A plant receptor detects a microbial pattern, while a pathogen effector attempts to suppress defence.

A resistance protein can detect effector-associated disturbance and trigger stronger immunity.

Plants therefore possess layered immune recognition without antibodies or lymphocytes.

All circulating immune cells ultimately derive from haematopoietic stem cells. These self-renewing cells generate progenitors that progressively commit to lymphoid, myeloid and other blood-cell lineages.

Growth factors and tissue niches regulate survival, proliferation and differentiation. Mature neutrophils, monocytes, B cells, T cells and other populations therefore share a developmental origin despite very different functions.

Bone marrow is both a production site for blood cells and the major site of B-cell development in mammals.

Immature T cells arriving in the thymus rearrange receptor genes and pass through selection processes before entering the circulation.

Positive selection preserves cells capable of recognising self MHC, while strong recognition of self peptide-MHC can trigger negative selection.

The result is a peripheral T-cell population that can work with the host's MHC while being less strongly self-reactive.

Lymph enters nodes through afferent vessels carrying antigen and antigen-presenting cells from tissues. B-cell follicles and T-cell zones create organised meeting places for rare antigen-specific lymphocytes.

Activated cells proliferate and interact with specialised stromal and antigen-presenting cells before effector cells and antibodies leave the node.

Organisation increases efficiency: immune cells do not need to search the entire body randomly for their matching antigen.

The spleen filters blood rather than lymph. Its white pulp supports immune responses to blood-borne antigens, while red pulp participates in removal of ageing red cells.

Splenic marginal regions are strategically positioned for rapid recognition of circulating microbes.

Loss of splenic function particularly compromises defence against some encapsulated bacteria.

After B-cell activation, germinal centres can form within lymphoid follicles. Rapidly dividing B cells undergo mutation, selection and differentiation.

Cells compete for antigen and T-cell help, favouring clones with improved receptor affinity.

This microanatomical process generates affinity-matured memory B cells and long-lived plasma cells.

Not all plasma cells disappear after an acute response. Some migrate to supportive niches, particularly in bone marrow, and secrete antibody for long periods.

These cells can maintain serum antibody even without repeated antigen exposure.

Durable vaccine protection can therefore reflect both persistent antibody from plasma cells and rapid recall by memory cells.

Memory T cells are heterogeneous. Some circulate through lymphoid organs, others patrol peripheral tissues, and tissue-resident memory cells remain near previous sites of infection.

Their location and activation threshold permit faster responses than naïve T cells.

Memory is therefore anatomical as well as numerical; strategically placed cells can respond before newly activated lymphocytes arrive.

When a T cell recognises an antigen-presenting cell, receptors and adhesion molecules organise at the contact interface.

This structured interaction concentrates T-cell receptor signalling, co-stimulation and secreted molecules toward the partner cell.

The synapse improves specificity and allows prolonged communication needed for lymphocyte activation.

Cytosolic proteins are degraded into peptides, many of which are transported into the endoplasmic reticulum and loaded onto MHC I molecules.

MHC I-peptide complexes move to the cell surface for inspection by CD8 T cells.

This pathway allows the immune system to sample proteins being made inside a cell, including viral or abnormal proteins.

Extracellular material internalised by antigen-presenting cells is degraded in vesicular compartments. MHC II molecules acquire peptides in these compartments before reaching the surface.

CD4 T cells inspect the displayed peptides and provide help appropriate to the detected threat.

Separation of MHC I and II pathways helps direct different T-cell effector functions.

Certain dendritic cells can present externally acquired antigens on MHC I molecules, a process called cross-presentation.

This permits activation of naïve CD8 T cells even when the dendritic cell itself is not productively infected.

The mechanism is important for antiviral and anti-tumour responses and for some vaccine strategies.

B-cell activation is influenced by molecules that supplement antigen-receptor signalling. Complement-tagged antigen can engage co-receptors and lower the threshold for activation.

This links innate complement recognition with adaptive B-cell responses.

The immune system therefore integrates multiple signals rather than treating receptor binding as an isolated event.

Protein antigens internalised by B cells can be processed and presented to helper T cells. Cognate T-cell help provides signals for proliferation, class switching, germinal-centre formation and memory.

These responses often produce high-affinity antibodies and durable memory.

They contrast with some T-independent responses, which can generate antibody with more limited class switching and memory.

Certain repetitive non-protein antigens can strongly cross-link B-cell receptors and activate selected B cells without conventional T-cell help.

Responses are commonly dominated by IgM and may generate weaker memory, especially in young children.

Conjugate vaccines convert important polysaccharide antigens into T-dependent forms by attaching them to carrier proteins.

A poorly immunogenic bacterial polysaccharide is chemically linked to a protein carrier. A B cell recognising the polysaccharide internalises the conjugate and presents carrier-derived peptides to helper T cells.

T-cell help then supports class switching, affinity maturation and memory against the polysaccharide target.

This immunological design substantially improves protection against encapsulated bacteria in populations that respond poorly to plain polysaccharide.

Activated lymphocytes express inhibitory receptors that reduce signalling when they engage appropriate ligands.

These checkpoints limit prolonged immune activation and protect tissues from uncontrolled responses.

Tumours can exploit inhibitory pathways, while therapeutic checkpoint blockade can restore anti-tumour responses at the cost of possible autoimmune-like inflammation.

Inflammatory cytokines act on the liver and other tissues to alter concentrations of plasma proteins during infection or injury.

Some acute-phase proteins recognise microbial surfaces, activate complement or alter iron availability.

Systemic innate responses therefore extend beyond leukocytes at the local infection site.

Inflammatory mediators can reset hypothalamic temperature regulation and produce fever.

Moderate fever can alter microbial growth and immune-cell function, but very high temperature can be harmful to the host.

Fever is a regulated host response rather than simply heat produced by microorganisms.

Virus-infected cells and innate sensors can induce type I interferons. These cytokines signal neighbouring cells to express antiviral proteins.

The induced state can inhibit viral entry, protein synthesis or genome replication depending on the effector pathway.

Interferons buy time before adaptive antiviral lymphocytes expand.

Some anatomical sites limit conventional inflammatory responses because tissue damage there would have especially severe consequences.

Physical barriers, local inhibitory signals and restricted immune-cell traffic contribute.

Privilege is relative rather than absolute; infection or injury can still provoke immunity in these sites.

Repeated exposure to harmless dietary antigens normally does not provoke damaging systemic immunity.

Mucosal antigen presentation, regulatory cells and local cytokines favour non-inflammatory responses.

Failure of appropriate mucosal tolerance can contribute to pathological responses against otherwise harmless material.

Commensal microorganisms educate and shape immune development, especially at barrier surfaces. They compete with pathogens and generate metabolites that influence immune cells.

The immune system simultaneously restricts microbiota from invading tissues while tolerating their presence at appropriate sites.

Disruption of this balance can alter susceptibility to infection and inflammatory disease.

Antibodies bind antigens on a target cell and expose Fc regions. Effector cells bearing Fc receptors, such as NK cells, recognise the coating and release cytotoxic molecules.

The antibody supplies specificity while the effector cell supplies killing capacity.

ADCC is another example of cooperation between humoral recognition and cellular effectors.

Complement fragments attached to immune complexes help bind them to receptors on blood cells for transport to organs where phagocytes remove them.

Failure of efficient clearance can increase tissue deposition and inflammation.

Complement therefore protects not only by attacking microbes but also by handling products of adaptive immune reactions.

Some pathogens alter dominant surface antigens during infection or across transmission cycles.

Previously generated antibodies may then bind poorly to the new variant, permitting continued replication.

Variation creates challenges for durable natural immunity, diagnostics and vaccine design.

Some pathogens persist in a nonproductive or restricted state after acute infection. Immune responses can suppress reactivation without completely eliminating the organism.

When immune control weakens, latent infection can reactivate.

Protection therefore sometimes means continuous containment rather than sterilising elimination.

Persistent intracellular microbes or indigestible antigens can trigger organised collections of macrophages, lymphocytes and other cells.

T-cell cytokines activate macrophages and help wall off material that cannot be rapidly cleared.

Granulomas protect by containment but can also impair organ function when extensive.

Severe infection can provoke widespread inflammatory and vascular responses that damage host organs.

Pathogen products initiate innate sensing, but tissue injury results partly from dysregulated host mediators, coagulation and endothelial dysfunction.

The example demonstrates that stronger immunity is not always better; appropriate magnitude and regulation are essential.

Ageing alters lymphocyte production, repertoire diversity, memory composition and innate-cell function.

Older adults can show weaker responses to new antigens and altered vaccine responsiveness, while chronic inflammatory activity may increase.

Vaccine schedules and formulations can therefore be tailored to age-related immune biology.

Newborn immune systems are functional but differ quantitatively and qualitatively from adult systems. Maternal antibody provides temporary support while infant responses mature.

Some vaccine antigens produce weaker responses early in life, and maternal antibody can sometimes interfere with particular vaccine responses.

Immunisation schedules account for disease risk, immune maturation and persistence of maternal protection.

Protein-energy malnutrition and deficiencies of selected micronutrients can impair barrier integrity, lymphocyte responses and innate defence.

Infection can in turn worsen nutritional status through reduced intake and increased metabolic demand.

This two-way relationship helps explain why nutrition is a major modifier of infectious-disease outcome.

Glucocorticoids and other endocrine signals influence cytokine production, lymphocyte trafficking and inflammatory responses.

Therapeutic glucocorticoids exploit these effects to suppress harmful inflammation or autoimmunity.

Prolonged or high-level immunosuppression can increase susceptibility to opportunistic infection.

Tumour cells accumulate altered proteins and stress signals that can be recognised by T cells or innate effectors.

Tumours can escape by losing antigens, reducing presentation, recruiting suppressive cells or engaging immune checkpoints.

Modern immunotherapy attempts to restore or redirect immune recognition while limiting damage to normal tissue.

A monoclonal antibody preparation contains molecules with one defined antigen-binding specificity derived from a single selected clone or recombinant sequence.

Such antibodies are used in diagnosis, research and therapy because their specificity and manufacturing properties can be standardised.

Therapeutic antibodies can neutralise soluble molecules, block receptors, recruit immune effectors or deliver attached agents.

Polyclonal antisera contain antibodies produced by many B-cell clones against multiple epitopes on an antigen.

They can provide strong overall binding and tolerate small antigen changes, but batch composition can vary.

The contrast with monoclonal reagents is important in diagnostic assay design and reagent quality.

Classical hybridoma technology fuses an antibody-producing B cell with an immortal myeloma cell, combining antibody specificity with continuous growth.

Individual hybrid cells can be cloned and screened for the desired antibody.

The method transformed diagnostic immunology by enabling reproducible monoclonal antibody production.

Antibody genes can be cloned and engineered to alter affinity, Fc function, species origin or molecular size.

Humanised and fully human therapeutic antibodies reduce some immune responses against foreign antibody sequences.

Engineering demonstrates how molecular biology extends classical immunological specificity into designed medicines.

A continuous assay signal must often be converted into positive, negative or equivocal categories using a cut-off.

Changing the cut-off changes the balance between sensitivity and specificity.

Cut-offs should be established and validated for the assay's intended purpose rather than chosen after seeing the desired result.

A receiver operating characteristic curve compares sensitivity and false-positive rate across multiple possible thresholds.

It helps visualise the trade-off between detecting disease and incorrectly classifying healthy individuals.

The optimal threshold depends on clinical purpose and consequences of each type of error, not only mathematical performance.

Diagnostic evidence modifies an existing probability rather than creating certainty from nothing.

A positive result for a rare disease in a low-risk person has a different meaning from the same result in a strongly exposed symptomatic person.

Good diagnostic immunology therefore begins before the assay, with selection of an appropriate patient or sample.

Internal controls detect whether reagents, instruments and procedural steps perform as expected within a run.

External quality assessment compares laboratory performance with independent materials or peers.

Reliable diagnosis requires both analytical technology and a quality system capable of detecting drift and error.

Haemolysis, contamination, incorrect storage, wrong tube type or delayed processing can alter immunological test results.

No sophisticated assay can fully repair a specimen that no longer represents the patient's biological state.

Pre-analytical quality is therefore part of diagnostic immunology, not merely a transport issue.

Human blood and body fluids may contain infectious agents regardless of the test being requested.

Risk assessment, barriers, sharps control, decontamination and appropriate waste handling reduce occupational exposure.

Universal or standard precautions are based on the principle that unknown infection status should not determine basic safe practice.

A master seed is a well-characterised biological source from which working seeds are derived for routine production.

Limiting passage from a controlled source reduces genetic drift and contamination risk.

Documentation links each production lot back to its authorised biological starting material.

For an inactivated vaccine, the process must abolish infectivity while preserving antigenic structures needed for immunity.

Insufficient inactivation creates safety risk, whereas excessive chemical or physical treatment can destroy useful epitopes.

Validation therefore demonstrates both complete inactivation under defined conditions and acceptable antigen quality.

Attenuation reduces a pathogen's capacity to cause disease while retaining enough biological activity to stimulate immunity.

Attenuation can arise through classical passage, targeted genetic modification or other platform-specific methods.

Because live attenuated organisms can replicate, their safety profile differs from non-replicating vaccines, particularly in severely immunocompromised hosts.

Recombinant or culture-derived vaccine antigens are separated from host-cell proteins, nucleic acids, media components and process impurities.

Purification steps must recover sufficient antigen while reducing contaminants to acceptable levels.

Analytical assays then confirm identity, purity and potency rather than assuming that a clear solution is pure.

Potency measures the biological activity relevant to a vaccine's ability to induce the intended response under defined test conditions.

It can be assessed by validated in vivo or in vitro methods depending on the product.

Potency is distinct from antigen quantity: structurally damaged antigen may be present but biologically ineffective.

Products intended for injection require stringent control of microbial contamination. Some vaccine platforms also require specialised tests for adventitious agents.

Aseptic processing prevents contamination after sterilising steps where final sterilisation would damage the biological product.

Environmental monitoring and process validation therefore form part of manufacturing assurance.

Purified antigen may be combined with buffers, stabilisers, preservatives where appropriate and adjuvants before filling.

Formulation protects antigen during storage and creates suitable delivery properties.

Components must be compatible; an excipient that stabilises one antigen can destabilise another.

Poultry or livestock programmes may use routes such as drinking water, spray, injection or other species-appropriate delivery methods.

Mass delivery increases practicality but introduces variability in dose uptake and handling.

Programme success therefore depends on vaccine quality, administration technique, animal health, maternal antibody and field epidemiology.

Young animals can receive maternal antibody through placenta, colostrum or both depending on species.

This protects early life but can neutralise some vaccine antigens before the young animal mounts its own response.

Veterinary schedules therefore consider the expected decline of maternal antibody and timing of disease exposure.

Human, animal and environmental health are connected through shared pathogens, reservoirs and antimicrobial pressures.

Vaccinating animals can protect animal productivity and sometimes reduce zoonotic transmission to people.

Immunology therefore contributes to disease control beyond individual clinical treatment.

Innate immunity is immediately available and uses germ-line encoded pattern-recognition receptors. Adaptive immunity develops through clonally distributed B- and T-cell receptors generated by somatic gene rearrangement.

Innate responses guide adaptive activation through antigen presentation, cytokines and co-stimulation. Adaptive antibodies then strengthen innate mechanisms such as phagocytosis and complement activation.

The two systems are therefore analytically distinct but biologically interdependent.

Humoral immunity is mediated principally by antibodies in extracellular fluids. Cell-mediated immunity depends especially on T lymphocytes and activated cellular effectors.

Antibodies excel at neutralising extracellular toxins and microbes, while cytotoxic T cells recognise infected host cells and helper T cells activate other leukocytes.

Many infections require both arms at different stages.

An antigen is recognised specifically by an antibody or antigen receptor, whereas an immunogen induces an immune response.

Every effective immunogen contains antigenic determinants, but a small hapten can be antigenic without being strongly immunogenic alone.

The distinction prevents the common error of treating binding and immune induction as identical properties.

An epitope is the part of an antigen recognised by an immune receptor. A paratope is the complementary binding surface on an antibody or receptor.

One complex antigen can contain many epitopes and stimulate many lymphocyte clones.

Specificity arises from molecular complementarity between epitope and paratope.

Affinity concerns one binding interaction, while avidity is the combined strength of multiple interactions.

Multivalent IgM can bind strongly overall through avidity despite individual sites having lower affinity than mature IgG.

Laboratory assays can reflect both properties.

Active immunity results from the recipient's own lymphocyte response and generates memory. Passive immunity transfers preformed antibodies and acts immediately.

Vaccination is usually active; maternal IgG and therapeutic immunoglobulin are passive.

Passive protection is temporary because transferred antibodies decay and no recipient memory is created.

A primary response begins with rare naïve clones and has a longer lag. A secondary response recruits memory cells generated earlier.

Secondary antibody responses are commonly faster, larger and enriched for high-affinity class-switched antibodies.

This difference is a functional demonstration of immunological memory.

MHC I occurs on most nucleated cells and presents mainly intracellularly derived peptides to CD8 T cells. MHC II is concentrated on professional antigen-presenting cells and presents mainly internalised antigen to CD4 T cells.

Both bind peptides and display them at the cell surface, but their processing pathways and T-cell partners differ.

The division helps direct cytotoxic responses toward infected cells and helper responses toward coordinating cells.

Both arise from haematopoietic precursors and use rearranged antigen receptors. B cells mature primarily in bone marrow, whereas T cells mature in thymus.

B-cell receptors can recognise native antigen and secreted antibody retains that specificity. Conventional T-cell receptors recognise antigen as peptide-MHC complexes and are not secreted as effectors.

Their cooperation is central to high-quality antibody responses.

Plasma cells are specialised for high-rate antibody secretion, while memory B cells retain antigen receptors and respond rapidly to later exposure.

Some plasma cells are short-lived and others persist for years; memory cells can re-enter proliferative responses and generate new plasma cells.

Long-term humoral immunity therefore has two complementary cellular foundations.

CD4 T cells recognise peptide-MHC II and principally coordinate immunity through helper and regulatory functions. CD8 T cells recognise peptide-MHC I and commonly mediate cytotoxicity.

Both require antigen-specific receptor recognition and can form memory.

Their different MHC restrictions align them with distinct sources of antigen.

Both can kill abnormal host cells through cytotoxic granules. Cytotoxic T cells use clonally rearranged antigen-specific receptors recognising peptide-MHC I, whereas NK cells integrate germ-line encoded activating and inhibitory receptors.

NK cells respond rapidly without prior antigen-specific priming and can kill antibody-coated targets through Fc receptors.

They provide complementary surveillance of infected or transformed cells.

Central tolerance acts during lymphocyte development in bone marrow or thymus, removing or altering strongly self-reactive clones.

Peripheral tolerance controls self-reactive cells that escaped central selection through anergy, deletion, regulatory cells and inhibitory pathways.

Redundancy is necessary because no developmental screen can present every self antigen perfectly.

Immunisation describes the process of becoming protected through active vaccination or, in broader usage, passive antibody administration. Vaccination specifically refers to administration of a vaccine.

A person can receive vaccine without developing adequate immunity, for example because of severe immunosuppression or product failure.

Precise language distinguishes the intervention from the resulting biological state.

Live attenuated organisms replicate to a limited extent and often induce strong humoral and cellular responses. Inactivated organisms cannot replicate and generally have a different safety and dosing profile.

Live vaccines can be unsuitable for some severely immunocompromised individuals, while inactivated products may require adjuvant and boosters.

Neither platform is universally superior; the pathogen and target population determine suitability.

Subunit vaccines contain selected antigenic components. Conjugate vaccines are a specialised design in which a poorly immunogenic polysaccharide is linked to a protein carrier.

The carrier recruits T-cell help, enabling class switching and memory against the polysaccharide.

Conjugation is an immunological solution to weak infant responses to plain polysaccharide.

Sensitivity asks how often diseased individuals test positive; specificity asks how often non-diseased individuals test negative.

Increasing a continuous test threshold can improve specificity while reducing sensitivity, or vice versa.

The desired balance depends on whether missing disease or generating false alarms has greater consequence.

Sensitivity is measured among people who truly have disease, whereas positive predictive value is measured among people whose test is positive.

PPV depends strongly on prevalence and therefore changes between populations even when sensitivity and specificity remain stable.

Confusing these measures leads to incorrect claims about what a positive result means.

Agglutination cross-links particulate antigens into visible clumps; precipitation forms lattices from soluble antigen and antibody.

Both require suitable antigen-antibody proportions and can fail in zones of excess.

The physical state of antigen distinguishes the classical reactions.

Direct immunofluorescence labels the antigen-specific primary antibody. Indirect immunofluorescence uses an unlabelled primary antibody followed by a fluorescent anti-immunoglobulin reagent.

Indirect methods can amplify signal because multiple secondary antibodies may bind one primary antibody.

Direct methods involve fewer binding steps but require a separately labelled reagent for each specificity.

Autoimmunity targets self antigens, whereas allergy is an inappropriate response to otherwise harmless environmental antigens.

Both reflect failure of normal immune discrimination or regulation and can involve antibodies, T cells or inflammatory mediators.

Their antigens differ fundamentally even when some effector mechanisms overlap.

Immunodeficiency describes inadequate immune function arising from inherited or acquired defects. Immunosuppression describes reduction of immune activity and may be deliberately therapeutic.

A transplant recipient may be intentionally immunosuppressed and consequently functionally immunodeficient against selected infections.

The terms overlap in effect but differ in cause and purpose.

In graft rejection, recipient immunity attacks donor tissue. In graft-versus-host disease, immunocompetent donor cells attack recipient tissues.

GVHD is especially relevant to haematopoietic transplantation because the graft contains functional lymphocytes.

The direction of immune attack is the essential distinction.

Type I reactions are rapid and driven by IgE-sensitised mast cells. Type IV reactions are T-cell mediated and typically develop over a longer period.

Both can occur at skin surfaces but differ in timing, mediators and diagnostic approaches.

Calling every skin allergy 'immediate allergy' ignores these mechanisms.

Neutralisation blocks a microbial or toxin function directly through antibody binding. Opsonisation coats a target so phagocytes recognise it efficiently.

Neutralisation can prevent a virus from entering a cell without phagocytosis; opsonisation usually requires an effector cell to complete clearance.

One antibody can sometimes contribute to both mechanisms depending on its epitope and Fc properties.

Immunogenicity measures immune responses such as antibody or T-cell activity after vaccination. Efficacy measures reduction in a clinical outcome under study conditions.

A vaccine can generate measurable antibody without that marker perfectly predicting protection.

Immune correlates are useful only when evidence links them to meaningful protection.

Sterilising immunity prevents establishment of infection, while disease-modifying immunity may allow infection but prevent severe illness.

Vaccines need not block every infection to have major public-health value.

The desired endpoint depends on pathogen biology and feasible immune mechanisms.

Both use immunological memory, controlled antigens and quality-assured manufacturing. Veterinary programmes additionally span species with different physiology, husbandry and delivery systems.

Mass vaccination of herds or flocks can prioritise population protection and economic disease control.

One Health connects veterinary vaccination with food security and control of zoonotic infections.

Vertebrates combine innate recognition with somatically diversified adaptive lymphocytes and antibodies. Plants rely on germ-line encoded receptors, local cellular defences and systemic signalling.

Plants can show immune memory-like priming but do not possess B cells, T cells or immunoglobulins.

The comparison shows that effective biological defence evolved through different architectures.

The same immune mechanism can protect at appropriate magnitude and cause disease when excessive, prolonged or misdirected.

Complement destroys microbes but can injure host tissue; Th2 responses oppose helminths but mediate allergy; T cells clear infection but can reject grafts.

Immunology is therefore the study of regulated defence, not simply maximal immune activation.

Entry and Immediate Recognition

When a microorganism crosses an epithelial barrier, resident macrophages, dendritic cells and epithelial cells detect conserved microbial patterns. Local mediators increase vascular permeability and recruit neutrophils and monocytes. Complement may become activated directly on the microbial surface. At this stage the response is rapid but not yet based on expanded antigen-specific lymphocyte clones.

Antigen Capture and Presentation

Dendritic cells take up microbial material, receive innate activation signals and migrate to draining lymph nodes. There they display microbial peptides on MHC molecules. Naïve T cells continuously recirculating through lymphoid tissue test these complexes with their receptors. Only rare clones with suitable specificity receive receptor, co-stimulatory and cytokine signals and begin clonal expansion.

B-Cell Recruitment

B cells bind intact antigen through surface immunoglobulin. For many protein antigens, the B cell internalises the antigen, presents carrier-derived peptides to helper T cells and receives signals that drive proliferation. Early plasma cells produce antibody, while germinal-centre reactions later support class switching, affinity maturation and memory.

Effector Phase

Antibodies neutralise extracellular pathogens or toxins, coat targets for phagocytosis and can recruit complement. Activated helper T cells strengthen macrophage and B-cell functions. Cytotoxic T cells remove infected host cells when intracellular antigens are displayed by MHC I. The dominant mechanism depends on where the pathogen lives and how it causes disease.

Contraction and Memory

When antigen burden falls, most short-lived effector cells die and inflammatory signals decline. Regulatory mechanisms limit continued tissue injury. A smaller population of memory B and T cells persists, and long-lived plasma cells may continue antibody secretion. Re-exposure therefore begins from a quantitatively and qualitatively improved state.

Product Design

Vaccine development begins by defining the disease target and identifying an antigen or biological platform capable of inducing useful immunity. Developers consider whether protection requires neutralising antibody, mucosal immunity, T-cell responses or a combination. Platform choice also considers safety in the intended population and feasibility of reproducible manufacture.

Controlled Biological Starting Material

Live organisms, viral vectors, production cell lines or recombinant expression systems are maintained through characterised master and working banks. Identity, genetic stability and freedom from relevant contaminants are established. The bank system limits uncontrolled passage and provides traceability for later production lots.

Upstream Production

Cells or microorganisms are propagated under controlled conditions. Parameters such as temperature, pH, nutrients, aeration and harvest time are monitored according to the platform. The aim is reproducible production of the antigen or vector rather than simply maximum biomass.

Inactivation or Attenuation Where Applicable

Inactivated vaccines require a validated process that removes infectivity while preserving immunologically important structures. Live attenuated platforms instead rely on stable reduction of pathogenic potential. Recombinant subunit and nucleic-acid platforms avoid whole pathogenic organisms in the final product but introduce their own manufacturing controls.

Purification

Harvest material can contain host-cell proteins, nucleic acids, media components and process reagents. Filtration, chromatography, precipitation, centrifugation or other operations reduce impurities while retaining antigen. The exact sequence is product-specific and must be validated.

Formulation and Filling

Purified antigen is placed into a formulation that preserves activity and may contain an adjuvant or stabiliser. The bulk product is filled into final containers under controlled conditions. Aseptic operations are especially important for biological products that cannot undergo harsh terminal sterilisation.

Quality Assessment

Each product has specifications for identity, potency, purity, safety, sterility or microbial quality and other attributes appropriate to the platform. Analytical methods must themselves be suitable for their intended purpose. Release occurs only when the lot satisfies established requirements.

Storage and Distribution

Stability studies establish storage conditions and shelf life. Temperature-sensitive products enter a monitored cold chain. Manufacturing quality can be lost after release if transport or storage damages antigen, which is why distribution is part of vaccine assurance.

Human and Animal Production

The broad biological principles apply to both human and veterinary vaccines, but species, disease ecology, dose, administration route and regulatory framework differ. Veterinary programmes may require economical mass delivery to large populations, while human products may use schedules designed for infancy, adulthood, pregnancy, travel or special clinical risk.

1. National Universities Commission. Core Curriculum and Minimum Academic Standards for the Nigerian University System: Sciences. MCB 307 Immunology.
2. Abbas, A. K., Lichtman, A. H. & Pillai, S. Cellular and Molecular Immunology.
3. Murphy, K. & Weaver, C. Janeway's Immunobiology.
4. Delves, P. J. et al. Roitt's Essential Immunology.
5. Parham, P. The Immune System.
6. Male, D. et al. Immunology.
7. World Health Organization guidance on vaccine manufacturing, quality and immunisation.

A useful way to understand immunity is as a regulated sequence rather than a collection of independent cells. Recognition occurs first, followed by signalling, clonal expansion or recruitment, effector action, contraction and memory. Failure at any stage changes the outcome.

If recognition fails, a pathogen may escape detection. If effector action is weak, infection persists. If contraction fails, inflammation can continue after the threat has disappeared.

This systems view helps students connect innate immunity, lymphocyte biology, complement, hypersensitivity and tolerance within one framework.

An immune mechanism useful in blood may be inappropriate at a delicate mucosal surface. Secretory IgA can neutralise microbes with relatively little inflammation, whereas intense complement and neutrophil activation could damage absorptive epithelium.

Likewise, cytotoxic T cells are valuable when pathogens hide inside host cells but unnecessary against a freely circulating toxin.

Protective immunity is therefore matched not only to the organism but also to its anatomical location.

Innate immunity acts within minutes to hours, while primary adaptive responses require days for rare specific clones to expand. Memory changes this timing during later encounters.

Diagnostic markers also appear at different times: pathogen antigen, IgM, IgG and cellular responses need not peak together.

Understanding kinetics prevents the mistaken assumption that one negative test at one time point excludes every stage of infection.

Immunological assays often produce colour, fluorescence, agglutination or bands, but a signal is meaningful only if controls show that reagents and procedure behaved correctly.

A negative control reveals background or contamination; a positive control demonstrates that the detection system can respond; calibration materials can connect signal to concentration.

Controls turn observation into interpretable evidence and are therefore part of the experiment rather than optional decoration.

An immune response can be valuable even when it does not prevent every organism from entering the body. Rapid memory responses may reduce pathogen load before severe tissue injury occurs.

Vaccines can therefore reduce severe disease, hospitalisation or transmission without necessarily blocking every detectable infection.

This distinction is essential when evaluating vaccine outcomes and avoids an unrealistically absolute definition of immunity.

For every immune topic, students should ask five questions: what is recognised, which receptor recognises it, which cell or molecule carries the signal, what effector mechanism follows, and how the response is regulated.

For complement, recognition begins through pathway-specific triggers and leads to C3 activation, opsonisation, inflammation or terminal lysis. For T cells, peptide-MHC recognition leads through co-stimulation to clonal expansion and specialised effector functions.

Using this framework makes unfamiliar examination questions easier because mechanisms can be reconstructed rather than memorised as disconnected lists.